Tanja Gruber

    Tanja A. Gruber, MD, PhD

    Assistant Member, St. Jude Faculty

    Departments

    Oncology

    Divisions

    Leukemia / Lymphoma

    Contact Information

    Tanja Gruber, MD, PhD
    Leukemia / Lymphoma
    MS 342, Room D4026F
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: tanja.gruber@stjude.org
    Phone: (901) 595-2252
    FAX: (901) 595-5947

    Education

    BS - Biology, University of Washington, Seattle, Washington (1995)
    BS - Biochemistry, University of Washington, Seattle, Washington (1995)
    PhD - Immunology, University of Southern California, Los Angeles, California (2001)
    MD - Medicine, University of Southern California, Los Angeles, California (2003)


    Research Interests

    Research in my laboratory focuses on two subtypes of high risk leukemia: MLL-rearranged (MLL-r) infantile acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia in non-Down syndrome patients (non-DS AMKL). These malignancies are driven by recurring chromosomal abnormalities that create the novel fusion genes MLL-AF4 (in MLL-r infant ALL) and CBFA2T3-GLIS2 (in non-DS AMKL). Our focus is on the mechanism whereby these fusions contribute to leukemogenesis with the long term goal of defining pathways and/or proteins to target therapeutically.


    Selected Publications

    Gruber TA, Gedman AL, Zhang J, Koss CS, Marada S, Ta H, Chen S-C, Su X, Ogden SK, Dang J, Gupta V, Andersson A, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ganti R, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau S, Ravandi-Kashani F, Kantarjian H, Nimer SD, Doehner K, Doehner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih L-Y, Liang D-C, Rubnitz J, Pui C-H, Mardis ER, Wilson RK, Downing JR. Transcriptome sequence analysis of pediatric acute megakaryoblastic leukemia identifies an inv(16)(p13.3;q24.3)-encoded CBFA2T3-GLIS2 fusion protein as a recurrent lesion in 30% of cases. Cancer Cell 22: 683–697, 2012.

    Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Research 70(19):7411-7420, 2010.

    Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim Y, Hofmann W, Li A, Storlazzi C, Jack H, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Muschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 206:1739-1753, 2009.

    Gruber TA, Shah AJ, Hernandez M, Abdel-Azim H, Crooks GM, Kapoor N, Gupta S, McKnight S, Schofield D, White D, Kohn DB. Clinical and genetic heterogeneity in Omenn Syndrome and severe combined immune deficiency. Pediatr Transplant 13:244-250, 2009.

    Gruber TA, Skelton DC, Kohn DB. Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Gene Ther 12:818-824, 2005.

    Gruber TA, Skelton DC, Kohn DB. Requirement for natural killer cells in CD40 ligand mediated rejection of Philadelphia chromosome positive acute lymphoblastic leukemia cells. J Immunol 168:73-80, 2002.

    Stripecke R, Skelton DC, Gruber T, Afar D, Pattengale PK, Witte O, Kohn DB. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 9:2049-2062, 1998.


    Last update: November 2012